Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13135986 | 1.00 | PTPRB (0.42) | PTPRBTRPA1AAK1SCN9ALIPG | |
| SCHEMBL2866531 | 0.79 | SYK (0.47) | — | |
| SCHEMBL13135987 | 0.79 | SYK (0.47) | — | |
| SCHEMBL15240604 | 0.79 | KMT2A (0.41) | PTPRBTRPA1AAK1MAPTATM | |
| SCHEMBL29265661 | 0.76 | IRAK4 (0.42) | TRPA1AAK1MAPTATMKMT2A | |
| SCHEMBL16410312 | 0.76 | IRAK4 (0.42) | TRPA1AAK1MAPTATMKMT2A | |
| SCHEMBL6903567 | 0.75 | KMT2A (0.42) | PTPRBTRPA1AAK1LIPGMAPT | |
| SCHEMBL16587895 | 0.75 | KMT2A (0.42) | PTPRBTRPA1AAK1LIPGMAPT | |
| SCHEMBL2408679 | 0.73 | HCAR2 (0.41) | PTPRBTRPA1LIPGMAPTATM | |
| SCHEMBL2406309 | 0.72 | KMT2A (0.40) | PTPRBTRPA1MAPTATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803801-B2 | Aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| EP-1854793-A1 | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY | Japan Tobacco, Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | SYK, BTK, ZAP70 | PTPRB 350/4885TRPA1 1534/4885AAK1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.